ACICLOVIR 250MG POWDER FOR SOLUTION FOR INFUSION

Active substance: ACICLOVIR

View full screen / Print PDF » Download PDF ⇩

Transcript
PACKAGE LEAFLET: INFORMATION FOR THE USER
Aciclovir 250mg Powder for Solution for Infusion
Read all of this leaflet carefully before you start using this medicine.
- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, nurse or pharmacist.
- This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them,
even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your
doctor, nurse or pharmacist.
The name of your medicine is Aciclovir 250mg Powder for Solution for Infusion. In the rest of this leaflet it is called
Aciclovir for Infusion (Infusion is a slow injection).
In this leaflet:
1. What Aciclovir for infusion is and what it is used for
2. Before you are given Aciclovir for Infusion
3. How Aciclovir for Infusion should be given
4. Possible side effects
5. How to store Aciclovir for Infusion
6. Further information

1. WHAT ACICLOVIR FOR INFUSION IS AND WHAT IT IS USED FOR
Aciclovir belongs to a group of medicines called antivirals. These medicines work by stopping viruses from spreading in
the body.
Aciclovir for Infusion is used to treat a variety of infections caused by herpes viruses:
• herpes infections in newborn infants and babies up to 3 months of age
• herpes infections in patients with a low resistance to disease
• inflammation of the brain caused by herpes virus
• severe infections of the genitals caused by herpes virus
• chickenpox and shingles
Aciclovir for Infusion is also used to prevent herpes infections in people who have a low resistance to disease.

2. BEFORE YOU ARE GIVEN ACICLOVIR FOR INFUSION
You should not be given aciclovir for infusion if:
• you are allergic to aciclovir, valaciclovir or to any of the other ingredients in this medicine (see section 6, Further
Information).
Speak to your doctor before being given aciclovir for infusion if you:
• have kidney problems as the dose may need to be modified according to how your kidneys are working.
• have a low resistance to disease (are immune compromised)
• are elderly
• are dehydrated (extremely thirsty)
• are on a low sodium diet (see ‘Important information for patients on a controlled sodium diet’ section below).
If any of the above statements apply to you, speak to your doctor or nurse before you are given Aciclovir for Infusion.

Taking other medicines
Taking another medicine while you are being given aciclovir for infusion can affect how it or the other medicine works.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those you
may have bought yourself without a prescription.
Please check with your doctor if you are taking any of the following or any other medication:
• Probenecid, a drug used to prevent gout (arthritis in the joints).
• Cimetidine, an anti-stomach ulcer drug.
• Drugs used in transplant patients (i.e. mycophenolate mofetil, ciclosporin and tacrolimus).
Pregnancy and breast-feeding
It is not certain if the use of Aciclovir during pregnancy causes birth defects. You should let your doctor know if you
think you may be pregnant or are trying for a baby.
Aciclovir can get into human breast milk. You should let your doctor know if you are breast-feeding or want to start
breast-feeding while you are having treatment with aciclovir for infusion.
Driving and using machines
Aciclovir for Infusion can cause confusion, hallucinations (seeing or hearing things that are not there), agitation, tremor
and drowsiness which may affect your ability to drive or use machines. If you are affected, do not drive or operate
machinery.
Important information for patients on a controlled sodium diet
Each vial contains 26mg of sodium. You should tell your doctor or pharmacist if you are on a controlled sodium diet.

3. HOW ACICLOVIR FOR INFUSION SHOULD BE GIVEN
Do not take by mouth.
Your doctor or nurse will prepare your injection by diluting it with water or salt solution, either in the vial or in another
container. The mixture is given by a slow injection into a vein (called an infusion) over an hour using a syringe-pump or
with a drip.
It is important to drink plenty of water after you have been given aciclovir infusion.
For the treatment of herpes infections, chickenpox or ‘shingles’ in adults
• The usual adult dose of Aciclovir for Infusion is 5mg per kg bodyweight every eight hours for five days.
• This dose is doubled to 10mg per kg every eight hours for:
- patients with low resistance to disease who have chicken pox or shingles
- patients with herpes inflammation of the brain (these patients may need ten days treatment).
For the treatment of herpes infections in newborn and babies up to 3 months old
• In the newborn and babies up to three months old, the dose is 20mg per kg of bodyweight every eight hours,
usually for 14 days for skin, eye and mouth infections, or 21 days if the disease is widely spread or has affected the
central nervous system.
For the treatment of chickenpox or herpes infections in children aged 3 months to 12 years
• For children aged 3 months to 12 years, the dose is 250mg per m² of body surface area, every eight hours, usually
for five days.

THE FOLLOWING INFORMATION IS INTENDED FOR HEALTHCARE PROFESSIONALS ONLY:

SUMMARY OF PRODUCT CHARACTERISTICS
1.
2.
3.
4.

NAME OF THE MEDICINAL PRODUCT

10 to 25 ml/min/1.73m2

QUALITATIVE AND QUANTITATIVE COMPOSITION

0(anuric) to 10 ml/min/1.73m2

Aciclovir 250mg Powder for Solution for Infusion

Each vial contains 250mg of aciclovir as the sodium salt
For a full list of excipients, see section 6.1

PHARMACEUTICAL FORM

Powder for solution for infusion.
White powder.

CLINICAL PARTICULARS

4.1. Therapeutic indications
Aciclovir for infusion is indicated for the treatment of Herpes simplex infections in immunocompromised patients
and severe initial genital herpes in the non-immunocompromised.
Aciclovir for infusion is indicated for the prophylaxis of Herpes simplex infections in immunocompromised
patients.
Aciclovir for infusion is indicated for the treatment of Varicella zoster infections.
Aciclovir for infusion is indicated for the treatment of herpes encephalitis.
Aciclovir for infusion is indicated for the treatment of Herpes simplex infections in the neonate and infant up to
three months of age.
4.2 Posology and method of administration
Route of administration: Slow intravenous infusion over one hour.
A course of treatment with aciclovir for infusion usually lasts five days, but this may be adjusted according to the
patient's condition and response to therapy. Treatment for herpes encephalitis usually lasts ten days. Treatment for
neonatal herpes usually lasts 14 days for mucocutaneous (skin-eye-mouth) infections and 21 days for
disseminated or central nervous system disease.
The duration of prophylactic administration of aciclovir for infusion is determined by the duration of the period at
risk.
Dosage
Dosage in adults:
Patients with Herpes simplex (except herpes encephalitis) or Varicella zoster infections should be given aciclovir for
infusion in doses of 5mg/kg bodyweight every eight hours provided renal function is not impaired (see Dosage in
renal impairment).
Immunocompromised patients with Varicella zoster infections or patients with herpes encephalitis should be
given aciclovir for infusion in doses of 10mg/kg bodyweight every eight hours provided renal function is not
impaired (see Dosage in renal impairment).
In obese patients dosed with intravenous aciclovir based on their actual body weight, higher plasma
concentrations may be obtained (see 5.2 Pharmacokinetic properties). Consideration should therefore be given to
dosage reduction in obese patients and especially in those with renal impairment or the elderly.
Dosage in children:
The dose of aciclovir for infusion for children aged between three months and 12 years is calculated on the basis
of body surface area.
Children three months of age or older with Herpes simplex (except herpes encephalitis) or Varicella zoster infections
should be given aciclovir for infusion in doses of 250 mg per square metre of body surface area every eight hours
if renal function is not impaired.
In immunocompromised children with Varicella zoster infections or children with herpes encephalitis, aciclovir for
infusion should be given in doses of 500 mg per square metre body surface area every eight hours if renal
function is not impaired.
The dosage of aciclovir for infusion in neonates and infants up to three months of age is calculated on the basis of
bodyweight.
The recommended regimen for infants treated for known or suspected neonatal herpes is aciclovir 20 mg/kg
body weight IV every eight hours for 21 days for disseminated and CNS disease, or for 14 days for disease limited
to the skin and mucous membranes.
Infants and children with impaired renal function require an appropriately modified dose, according to the degree
of impairment (see Dosage in renal impairment).
Dosage in the elderly:
The possibility of renal impairment in the elderly must be considered. In the elderly, total aciclovir body clearance
declines in parallel with creatinine clearance. Special attention should be given to dosage reduction in elderly
patients with impaired creatinine clearance.
Adequate hydration should be maintained.
Dosage in renal impairment:
Caution is advised when administering aciclovir for infusion to patients with impaired renal function. Adequate
hydration should be maintained.
Dosage adjustment for patients with renal impairment is based on creatinine clearance, in units of ml/min for
adults and adolescents and in units of ml/min/1.73m2 for infants and children less than 13 years of age. The
following adjustments in dosage are suggested:
Dosage adjustments in adults and adolescents:
Creatinine Clearance
Dosage
25 to 50 ml/min
The dose recommended above (5 or 10 mg/kg bodyweight) should be given
every 12 hours.
10 to 25 ml/min
The dose recommended above (5 or 10 mg/kg bodyweight) should be given
every 24 hours.
0 (anuric) to 10 ml/min
In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose
recommended above (5 or 10 mg/kg bodyweight) should be halved and
administered every 24 hours. In patients receiving haemodialysis the dose
recommended above (5 or 10 mg/kg bodyweight) should be halved and
administered every 24 hours and after dialysis.
Dosage adjustments in infants and children:
Creatinine Clearance
Dosage
25 to 50 ml/min/1.73m2
The dose recommended above (250 or 500 mg/m2 body surface area or
20 mg/kg body weight) should be given every 12 hours.

4.3.
4.4.

4.5.

4.6.

4.7.

4.8.

The dose recommended above (250 or 500 mg/m2 body surface area or
20 mg/kg body weight) should be given every 24 hours.
In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose
recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body
weight) should be halved and administered every 24 hours.
In patients receiving haemodialysis the dose recommended above (250 or
500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and
administered every 24 hours and after dialysis.

Administration
The required dose of aciclovir for infusion should be administered by slow intravenous infusion over a one-hour
period.
After reconstitution aciclovir for infusion may be administered by a controlled-rate infusion pump.
Alternatively, the reconstituted solution may be further diluted to give an aciclovir concentration of not greater
than 5 mg/ml (0.5% w/v) for administration by infusion.
For instructions on reconstitution and dilution of the product before administration see section 6.6.
Contraindications
Aciclovir for infusion is contraindicated in patients known to be previously hypersensitive to aciclovir and
valaciclovir, or to any of the excipients.
Special warnings and precautions for use
Use in patients with renal impairment and in elderly patients:
Aciclovir is eliminated by renal clearance, therefore the dose must be reduced in patients with renal impairment
(see section 4.2). Elderly patients are likely to have reduced renal function and therefore the need for dose
reduction must be considered in this group of patients. Both elderly patients and patients with renal impairment
are at increased risk of developing neurological side effects and should be closely monitored for evidence of these
effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see
section 4.8).
Prolonged or repeated courses of aciclovir in severely immune-compromised individuals may result in the
selection of virus strains with reduced sensitivity, which may not respond to continued aciclovir treatment.
In patients receiving aciclovir for infusion at higher doses (e.g. for herpes encephalitis), specific care regarding
renal function should be taken, particularly when patients are dehydrated or have any renal impairment.
Reconstituted aciclovir for infusion has a pH of approximately 11.0 and should not be administered by mouth.
Aciclovir for infusion contains no antimicrobial preservative. Reconstitution and dilution should therefore be
carried out under full aseptic conditions immediately before use and any unused solution discarded. The
reconstituted or diluted solutions should not be refrigerated.
This vial contains approximately 26mg of sodium in total. The sodium content should be taken into consideration
when prescribing to patients requiring sodium restriction.
Interaction with other medicinal products and other forms of interaction
No clinically significant interactions have been identified.
Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Any drugs administered
concurrently that compete with this mechanism may increase aciclovir plasma concentrations. Probenecid and
cimetidine increase the AUC of aciclovir by this mechanism, and reduce aciclovir renal clearance. However no
dosage adjustment is necessary because of the wide therapeutic index of aciclovir.
In patients receiving intravenous aciclovir, caution is required during concurrent administration with drugs which
compete with aciclovir for elimination, because of the potential for increased plasma levels of one or both drugs
or their metabolites. Increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate
mofetil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are
co-administered.
Care is also required (with monitoring for changes in renal function) if administering intravenous aciclovir with
drugs which affect other aspects of renal physiology (e.g. ciclosporin, tacrolimus).
Pregnancy and lactation
Pregnancy
The use of aciclovir should be considered only when the potential benefits outweigh the possibility of unknown
risks.
A post-marketing aciclovir pregnancy registry has documented pregnancy outcomes in women exposed to any
formulation of aciclovir. The registry findings have not shown an increase in the number of birth defects amongst
aciclovir exposed subjects compared with the general population, and any birth defects showed no uniqueness
or consistent pattern to suggest a common cause.
Fertility
There is no information on the effect of aciclovir on human female fertility. In a study of 20 male patients with
normal sperm count, oral aciclovir administered at doses of up to 1g per day for up to six months has been shown
to have no clinically significant effect on sperm count, motility or morphology.
Lactation
Following oral administration of 200mg five times a day, aciclovir has been detected in human breast milk at
concentrations ranging from 0.6 to 4.1 times the corresponding plasma levels. These levels would potentially
expose nursing infants to aciclovir dosages of up to 0.3 mg/kg bodyweight/day. Caution is therefore advised if
aciclovir is to be administered to a nursing woman.
Effects on ability to drive and use machines
Aciclovir for infusion is generally used in an in-patient hospital population and information on ability to drive and
operate machinery is not usually relevant. There have been no studies to investigate the effect of aciclovir on
driving performance or the ability to operate machinery. However, aciclovir can cause reversible neurological
reactions such as confusion, hallucinations, agitation, tremors, somnolence, psychosis and coma, which can all
affect the ability to drive and use machinery.
Undesirable effects
The frequency categories associated with the adverse events below are estimates. For most events, suitable data
for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on
the indication.
The following convention has been used for the classification of undesirable effects in terms of frequency:Very common ≥ 1/10, common ≥1/100 and <1/10, uncommon ≥1/1,000 and <1/100, rare ≥1/10,000 and
<1/1,000, very rare <1/10,000.

Measure bar should be 150mm at 100% scale
Customer

Wockhardt

Colours Used

Description

Aciclovir 250mg Leaflet

Black

Item Code
Profile

8pt

Market

UK

Language

IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING
FULL APPROVAL OF DESIGN AND TEXT.

297 x 420mm

Min. Point Size

Warning! We cannot accept responsibility for any errors
in this proof after approval. Whilst we take extreme care
at all times to ensure accuracy to our clientʼs brief,
the final responsibility must be taken by our client.

-

Size

English

Proof By

Michael Casingena

Proof No.

Two

Date

18/06/2013

Keyline (Does not print)

103376/5

Artwork No.

451617

Pharma
Code

N/A

-



This can be doubled to 500mg per m² of body surface area every eight hours for:
- children with low resistance to disease who have chickenpox
- children with herpes inflammation of the brain
Your dosage may need to be reduced if you have kidney problems, are obese or are elderly.
Your doctor will decide the dose which is best for you. If you do not understand, or are in any doubt, ask your doctor or
nurse.
If you are given more aciclovir for infusion than you should
A doctor or a nurse will usually give you this medicine. If you are given too much Aciclovir for Infusion you may feel
confused or agitated, or suffer from hallucinations (imagining things) or seizures. Too much Aciclovir for Infusion can
also cause changes in blood chemicals, kidney failure and loss of consciousness. If you have been given too much
medicine, you may be put on a kidney machine to reduce the amount of Aciclovir for Infusion in your blood.
If you think you may have received too much aciclovir for infusion, please tell your doctor or nurse at once.
If you think you have missed a dose of aciclovir for infusion
A doctor or a nurse will usually give you this medicine. If you think you have missed a dose, please tell your doctor or
nurse.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor
or pharmacist.

4. POSSIBLE SIDE EFFECTS

What Aciclovir for Infusion contains
Each vial contains 250mg of the active ingredient, aciclovir (as the sodium salt), as a powder.
The other ingredient is sodium hydroxide.
What Aciclovir for Infusion looks like and contents of the pack
The white powder comes in a glass vial with a rubber cap and metal/plastic seal. It is available in packs of 1, 5 or 10 vials.
Not all pack sizes may be marketed.
Other formats

5. HOW TO STORE ACICLOVIR FOR INFUSION
Aciclovir for Infusion must be kept out of the reach and sight of children.
• Aciclovir for Infusions should not be used after the expiry date given on the carton and the label on the small
glass container (vial). The expiry date refers to the last day of the month.
• Your doctor, nurse or pharmacist will be responsible for storing and preparing aciclovir before use and for checking
that the vials have not passed their expiry date.
• Aciclovir for Infusion should not be stored above 25°C. The vials should be kept in their outer carton, in order to
protect from light.
• Once the powder has been made into a solution the product should be used immediately. If this is not possible it
would generally not be stored for more than 24 hours at 2-8°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of
medicines no longer required. These measures will help to protect the environment.

6. FURTHER INFORMATION

Like many medicines, Aciclovir for Infusion may cause side effects in some patients, although not everybody gets them.
If you experience any of the following symptoms, tell your doctor or nurse immediately:
Very rare (affects less than 1 in 10,000 people):
· severe allergy, breathing problems or swelling of the face
Uncommon (affects less than 1 in 100 people)
· a fall in the number of blood cells may cause unexplained bleeding or bruising, sore throats, mouth
ulcers, or a low resistance to infections.

To listen to or request a copy of this leaflet in Braille, large print or audio please
call, free of charge:
0800 198 5000 (UK Only)
Please be ready to give the following information:

Other side effects include:
Common (affects less than 1 in 10 people)
• nausea and vomiting
• allergic reactions such as rashes, sensitivity to light and itching
• swelling, redness and tenderness at the site of injection.
Uncommon (affects less than 1 in 100 people)
• anaemia
Very rare (affects less than 1 in 10,000 people)
• headache or feeling dizzy
• diarrhoea or stomach pains
• feeling tired
• fever
• drowsiness, confusion, hallucinations (imagining things), feeling agitated, difficulty in controlling movements,
difficulty in speaking, personality changes and inability to concentrate, shaking, fits and loss of consciousness,
particularly in patients with other medical problems
• severe local inflammation leading to a breakdown of the skin at the site of injection if aciclovir leaks out of the vein
• liver and kidney problems. These may cause increases in the levels of various chemicals in the blood and yellowing
of the skin
• pain in your lower back, the kidney area of your back or just above your hip (renal pain).

Product Name
Aciclovir 250mg Powder for Solution for Infusion

This is a service provided by the Royal National Institute of Blind People.
Marketing Authorisation holder and manufacturer
Marketing Authorisation Holder: Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK.
Manufacturer: CP Pharmaceuticals Ltd, Ash Road North, Wrexham, LL13 9UF, UK.
This leaflet was last approved in October 2011.
103376/5

Blood and lymphatic system disorders
Uncommon: Decreases in haematological indices (anaemia, thrombocytopenia, leucopenia).
Immune system disorders
Very rare: Anaphylaxis.
Psychiatric and nervous system disorders
Very rare: Headache, dizziness, confusion, hallucinations, agitation, tremor, ataxia, dysarthria, somnolence,
psychotic symptoms, encephalopathy, convulsions and coma.
The above events are generally reversible and usually reported in patients with renal impairment or with other
predisposing factors (see section 4.4).
Vascular disorders
Common: Phlebitis.
Respiratory, thoracic and mediastinal disorders
Very rare: Dyspnoea.
Gastrointestinal disorders
Common: Nausea, vomiting
Very rare: Diarrhoea, abdominal pain.
Hepato-biliary disorders
Common: Reversible increases in liver-related enzymes
Very rare: Reversible increases in bilirubin, hepatitis and jaundice.
Skin and subcutaneous tissue disorders
Common: Rashes including photosensitivity, urticaria, pruritus
Very rare: Angioedema.
Renal and urinary disorders
Common: Increases in blood urea and creatinine
Rapid increases in blood urea and creatinine levels are believed to be related to peak plasma levels and the state
of hydration of the patient. To avoid this effect the drug should not be given as an intravenous bolus injection but
by slow infusion over a one hour period.
Very rare: Renal impairment, acute renal failure, renal pain
Adequate hydration of the patient should be maintained. Renal impairment developing during treatment with
aciclovir for infusion usually responds rapidly to rehydration of the patient and/or dosage reduction or withdrawal
of the drug. Progression to acute renal failure, however, can occur in exceptional cases.
Renal pain may be associated with renal failure and crystalluria.
General disorders and administration site conditions
Very rare: Fatigue, fever, local inflammatory reactions
Severe local inflammatory reactions sometimes leading to breakdown of the skin have occurred when
formulations of aciclovir for intravenous use have been inadvertently infused into extravascular tissues.
4.9. Overdose
Symptoms and Signs
Overdosage of intravenous aciclovir has resulted in elevations of serum creatinine, blood urea nitrogen and
subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma
have been described in association with overdosage.
Treatment
Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir
from the blood and may, therefore, be considered a management option in the event of symptomatic overdose.

5.

Reference Number
29831/0320

In a clinical study in which morbidly obese female patients (n=7) were dosed with intravenous aciclovir based on
their actual body weight, plasma concentrations were found to be approximately twice that of normal weight
patients (n=5), consistent with the difference in body weight between the two groups.
Cerebrospinal fluid levels are approximately 50% of corresponding plasma levels.
Plasma protein binding is relatively low (9 to 33%) and drug interactions involving binding site displacement are
not anticipated.
5.3. Preclinical safety data
The results of a wide range of mutagenicity test in vitro and in vivo indicate that aciclovir is unlikely to pose a
genetic risk to man.
Aciclovir was not found to be carcinogenic in long-term studies in the rat and the mouse.
Systemic administration of aciclovir in internationally accepted standard tests did not produce embryotoxic or
teratogenic effects in rabbits, rats or mice.
In a non-standard test in rats, foetal abnormalities were observed but only following such high subcutaneous
doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain.
Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have
been reported only at doses of aciclovir greatly in excess of those employed therapeutically. Two-generation
studies in mice did not reveal any effect of (orally administered) aciclovir on fertility.
There is no experience of the effect of aciclovir for infusion on human fertility. Aciclovir tablets have been shown
to have no definitive effect upon sperm count, morphology or motility in man.

6.

PHARMACEUTICAL PARTICULARS

6.1. List of excipients
Sodium hydroxide
6.2. Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
6.3. Shelf life
Unopened - Three years
For reconstituted solutions, chemical and physical in-use stability has been demonstrated for at least 24 hours at 25°C.
From a microbiological point of view, once opened, the product should be used immediately. If not used immediately,
in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than
24 hours at 2-8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.
Following dilution using the fluids detailed in section 6.6, chemical and physical in-use stability has been
demonstrated for up to 12 hours at 25°C. From a microbiological point of view the diluted solution should be
used immediately. If not used immediately in-use storage times and conditions are the responsibility of the user.
6.4. Special precautions for storage
Unopened: Do not store above 25°C
Keep the vials in the outer carton.
After reconstitution: Do not store above 25°C (see 6.3 Shelf Life).
6.5. Nature and contents of container
Packs* of one, five or ten Type II colourless glass 10ml vials stoppered with a chlorobutyl stopper and an
aluminium and polypropylene flip-off cap.
*Not all pack sizes may be marketed
6.6. Instructions for use and handling
Reconstitution:
Aciclovir 250mg for infusion should be reconstituted using 10ml of either Water for Injections PhEur or Sodium
Chloride Intravenous Infusion BP (0.9% w/v) to provide a solution containing 25mg aciclovir per ml.
From the calculated dose, determine the appropriate number and strength of vials to be used. To reconstitute
each vial add the recommended volume of infusion fluid and shake gently until the contents of the vial have
dissolved completely.
The reconstituted solution appears light yellow and slightly opalescent.
After reconstitution aciclovir powder for solution for infusion may be administered by a controlled-rate infusion pump.
Alternatively, the reconstituted solution may be further diluted to give an aciclovir concentration of not greater
than 5 mg/ml (0.5% w/v) for administration by infusion:
For further dilution, add the required volume of reconstituted solution to the chosen infusion solution, as
recommended below, and shake well to ensure adequate mixing occurs.
For children and neonates, where it is advisable to keep the volume of infusion fluid to a minimum, it is recommended
that dilution is on the basis of 4ml reconstituted solution (100mg aciclovir) added to 20 ml of infusion fluid.
For adults, it is recommended that infusion bags containing 100ml of infusion fluid are used, even when this
would give an aciclovir concentration substantially below 0.5% w/v. Thus, one 100 ml infusion bag may be used
for any dose between 250mg and 500mg aciclovir (10 and 20 ml of reconstituted solution) but a second bag
must be used for doses between 500 and 1000mg.
When diluted in accordance with the recommended schedules, aciclovir for infusion is known to be compatible
with the following infusion fluids:
sodium chloride intravenous infusion BP (0.45% and 0.9% w/v);
sodium chloride (0.18% w/v) and glucose (4% w/v) intravenous infusion BP
sodium chloride (0.45% w/v) and glucose (2.5% w/v) intravenous infusion BP
compound sodium lactate intravenous infusion BP (Hartmann's Solution).
Aciclovir for infusion, when diluted in accordance with the above schedule will give an aciclovir concentration not
greater than 0.5% w/v.
Since no antimicrobial preservative is included, reconstitution and dilution must be carried out under full aseptic
conditions, immediately before use, and any unused solution discarded.
Should any visible turbidity or crystallisation appear in the solution before or during infusion, the preparation
should be discarded.

PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties
ATC Code: J05A B01, Direct Acting Antiviral
Aciclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against human
herpes viruses, including Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), Epstein Barr virus
(EBV) and Cytomegalovirus (CMV). In cell culture aciclovir has the greatest antiviral activity against HSV-1, followed
(in decreasing order of potency) by HSV-2, VZV, EBV, and CMV.
The inhibitory activity of aciclovir for HSV-1, HSV-2, VZV and EBV is highly selective. The enzyme thymidine kinase
(TK) of normal, uninfected cells does not use aciclovir effectively as a substrate, hence toxicity to mammalian host
cells is low; however, TK encoded by HSV, VZV and EBV converts aciclovir to aciclovir monophosphate, a
nucleoside analogue, which is further converted to the diphosphate and finally to the triphosphate by cellular
enzymes. Aciclovir triphosphate interferes with the viral DNA polymerase and inhibits viral DNA replication with
resultant chain termination following its incorporation into the viral DNA.
5.2. Pharmacokinetic properties
In adults, the terminal plasma half-life of aciclovir after administration of aciclovir for infusion is about 2.9 hours.
Most of the drug is excreted unchanged by the kidney. Renal clearance of aciclovir is substantially greater than
creatinine clearance, indicating that tubular secretion, in addition to glomerular filtration, contributes to the renal
elimination of the drug.
9-carboxymethoxymethylguanine is the only significant metabolite of aciclovir and accounts for 10 to 15% of the
dose excreted in the urine.
When aciclovir is given one hour after 1g of probenecid the terminal half-life and the area under the plasma
concentration time curve, are extended by 18% and 40% respectively.
In adults, mean steady state peak plasma concentrations (Cmax,ss) following a one-hour infusion of 2.5 mg/kg, 5
mg/kg, and 10 mg/kg were 22.7 micromolar (5.1 microgram/ml), 43.6 micromolar (9.8 microgram/ml), and 92
micromolar (20.7 microgram/ml) respectively. The corresponding trough levels (Cmin,ss) 7 hours later were 2.2
micromolar (0.5 microgram/ml), 3.1 micromolar (0.7 microgram/ml) and 10.2 micromolar (2.3 microgram/ml)
respectively. In children over one year of age similar mean peak (Cmax,s) and trough (Cmin,ss) levels were observed
when a dose of 250 mg/m² was substituted for 5 mg/kg and a dose of 500 mg/m² was substituted for 10 mg/kg.
In neonates (0 to three months of age) treated with doses of 10 mg/kg administered by infusion over a one-hour
period every 8 hours the Cmax,s was found to be 61.2 micromolar (13.8 microgram/ml) and the Cmin,ss.to be 10.1
micromolar (2.3 microgram/ml). A separate group of neonates treated with 15 mg/kg every eight hours showed
approximate dose proportional increases, with a Cmax of 83.5 micromolar (18.8 microgram/ml) and Cmin of 14.1
micromolar (3.2 microgram/ml).
The terminal plasma half-life in these patients was 3.8 hours. In the elderly, total body clearance falls with
increasing age and is associated with decreases in creatinine clearance although there is little change in the
terminal plasma half-life.
In patients with chronic renal failure the mean terminal half-life was found to be 19.5 hours. The mean aciclovir
half-life during haemodialysis was 5.7 hours. Plasma aciclovir levels dropped approximately 60% during dialysis.

7.

8.
9.
10.

MARKETING AUTHORISATION HOLDER

Wockhardt UK Limited
Ash Road North
Wrexham LL13 9UF
United Kingdom

MARKETING AUTHORISATION NUMBER(S)

PL 29831/0320

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 6 May 2008

DATE OF REVISION OF THE TEXT
JUNE 2013.

103376/5

Measure bar should be 150mm at 100% scale
Customer

Wockhardt

Colours Used

Description

Aciclovir 250mg Leaflet

Black

Item Code
Profile

8pt

Market

UK

Language

IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING
FULL APPROVAL OF DESIGN AND TEXT.

297 x 420mm

Min. Point Size

Warning! We cannot accept responsibility for any errors
in this proof after approval. Whilst we take extreme care
at all times to ensure accuracy to our clientʼs brief,
the final responsibility must be taken by our client.

-

Size

English

Proof By

Michael Casingena

Proof No.

Two

Date

18/06/2013

Keyline (Does not print)

103376/5

Artwork No.

451617

Pharma
Code

N/A

-

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)